Vor Biopharma Inc. (VOR): R&D Expense
$321.53M
Year ended 2025-12-31
$76.85M
Trailing 12 months to 2026-06-30
+70.8%
3-year compound annual growth
+59.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $321.53M | +244.6% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $93.31M | -1.1% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $94.31M | +46.1% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $64.55M | +35.8% | 2024-03-20, From 2022-01-01 |
| 2021-12-31 | $47.53M | +50.3% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $31.62M | n/a | 2022-03-14, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $321.53M | +244.6% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $187.40M | +31.1% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.56M | +11.2% |
| ImmunityBio, Inc. (IBRX) | 2024-12-31 | $190.14M | -18.2% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $93.77M | -8.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $166.13M | -4.9% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $131.98M | -38.8% |
Compare VOR, RGNX, GLUE, CGEM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗